High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19

• المؤلفون الرئيسيون: Mario Karolyi (مؤلف), Sara Omid (مؤلف), Erich Pawelka (مؤلف), Bernd Jilma (مؤلف), Thomas Stimpfl (مؤلف), Christian Schoergenhofer (مؤلف), Hermann Laferl (مؤلف), Tamara Seitz (مؤلف), Marianna Traugott (مؤلف), Christoph Wenisch (مؤلف), Alexander Zoufaly (مؤلف)
• التنسيق: كتاب
• منشور في: Frontiers Media S.A., 2021-07-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Background: Despite lopinavir/ritonavir (LPV/RTV) demonstrating in-vitro activity against SARS-CoV-2, large trials failed to show any net clinical benefit. Since SARS-CoV-2 has an EC50 of 16.4 μg/ml for LPV this could be due to inadequate dosing.Methods: COVID-19 positive patients admitted to the ho...